摘要
目的 初步探讨血管内皮抑制素（ES）联合放化疗治疗晚期非小细胞肺癌（NSCLC）临床疗效及不良反应,评价其有效性及安全性.方法 回顾性分析哈尔滨医科大学肿瘤医院2009年2月至2012年2月收治的ⅢB～Ⅳ期的64例NSCLC患者,分为放化疗组及ES＋放化疗组.观察两组患者的近期疗效,比较两组的总有效率、中位生存时间、无进展生存时间及无瘤生存时间.结果 放化疗组39例,总有效率为76.9％;ES＋放化疗组25例,总有效率为84.0％（χ^2=0.47,P=0.492）.放化疗组与ES＋放化疗组中位生存时间、中位无进展生存时间、中位无瘤生存时间分别为11.52个月：16.51个月（χ^2=3.74,P=0.042）、7.32个月：10.37个月（χ^2=5.32,P=0.025）和5.21个月：7.57个月（χ^2=4.56,P=0.035）.主要药物不良反应均为血液学毒性及消化道反应,但两组间差异无统计学意义;放疗不良反应主要表现为1～2级放射性肺损伤及放射性食管炎（其中放化疗组出现1例3级放射性肺损伤）,两组间差异无统计学意义.结论 ES联合放化疗治疗晚期NSCLC可获得较好的近期临床疗效且不增加放化疗不良反应.
Objective To preliminary study clinical efficacy and toxicity of endostatin （ES） combined radiotherapy and chemotherapy in advanced non-small cell lung cancer （NSCLC）,and evaluate its effectiveness and safety.Methods We retrospectively reviewed 64 patients with Ⅲ B-Ⅳ stage NSCLC of Harbin Medical University Cancer Hospital from February 2009 to February 2012.The patients were divided into two groups：chemoradiotherapy group,39 patients and ES add chemoradiotherapy group,25 patients.The short-term effect,the total efficiency,median survival time,progression-free survival time and disease-free survival time were compared.Results The total effective rate of chemoradiotherapy group was 76.9%,while the total effective rate of ES add chemotherapy group was 84.0% （χ^2 =0.47,P =0.492）.Chemoradiotherapy group,compared to ES add chemotherapy group,the median survival time,median progression-free survival time,median disease-free survival time were 11.52 months vs 16.51 months （χ^2 =3.74,P =0.042）,7.32 months vs 10.37 months （χ^2 =5.32,P =0.025） and 5.21 months vs 7.57 months （χ^2 =4.56,P =0.035） respectively.The mainly adverse drug reactions were hematologic toxicity and gastrointestinal reactions,but there were no significant differences between the two groups; radiotherapy side effects mainly showed the grade 1 to 2 radiationinduced lung injury and radiation esophagitis （chemotherapy group had one case of grade 3 radiation-induced lung injury）,but also had no significant differences between the two groups.Conclusion ES combined chemoradiotherapy can achieve a better short-term clinical efficacy without increasing adverse effects of radiotherapy or chemotherapy in advanced non-small cell lung cancer.
出处
《国际肿瘤学杂志》
CAS
2014年第12期941-945,共5页
Journal of International Oncology
